Tilray announced the results of a medical study using Tilray 2:100 were published in the medical journal Annals of Clinical and Translational Neurology.
Tilray (NASDAQ:TLRY) announced the results of a medical study using Tilray 2:100, a medical cannabis oil, for the treatment of children with drug-resistant epilepsy (DRE) due to Dravet Syndrome were published in the medical journal Annals of Clinical and Translational Neurology.
As quoted in the press release:
“We are excited by the encouraging results of this study and the ability to already offer this highly concentrated [cannabidiol] CBD product to patients in Canada. We developed this product based on a strong existing evidence base that a combination cannabinoid product may have numerous benefits in this difficult to treat patient population,” said Catherine Jacobson, Director of Tilray’s Clinical Research Program. “In the participants who reached the target treatment dose there was a statistically significant reduction in motor seizures, and an increase in seizure-free days compared to those who did not reach the target dose. Promising clinically beneficial effects were observed, including a reduction in seizure frequency and improvements in certain aspects of adaptive functioning and quality of life measures.”
“This is an important study, providing valuable data about the safety and efficacy of a high CBD and low [tetrahydrocannabinol] THC medication to treat Dravet syndrome, a disorder with high morbidity and mortality,” said Orrin Devinsky, MD, Chair of Tilray’s Medical Advisory Board and Director of the Comprehensive Epilepsy Center at New York University Langone Medical Center.
Tilray 2:100 contains the highest concentration of cannabis-extracted CBD in a medical cannabis product available through Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). Tilray 2:100 has a target concentration of 100mg/ml CBD and 2mg/ml THC for a total cannabinoid amount of 4,000mg CBD and 80mg THC in each 40ml bottle.